Global Health Ventures Inc. (OTCBB: GHLV) does not try to reinvent the wheel. By acquiring and licensing currently outstanding healthcare
related technologies, GHLV bypasses much of the costly development stage and provides promising opportunities for further development and
re-licensing to pharmaceutical companies. GHLV develops proprietary platform technology that delivers drugs via the sublingual (under the
tongue) route, which delivers drugs to the bloodstream quickly and with minimal drug breakdown in the liver and gastro-intestinal system. Its
products under development include GLV-0901 for sexual enhancement in people who are not suffering from erectile dysfunction; GLV-0902, a
sublingual formulation of nicotine; GLV-0903, a stress reduction drug; and GLV-0904, an appetite-suppressant product. In our opinion, we
believe GHLV has the potential to trade much higher as it completes its business plan and brings new products to the market. Investors have the
potential to make huge profits from the stock, provided a larger drug or pharmaceutical company does not buy GHLV first.
Unique Process
GHLV is a specialty pharmaceutical company developing proprietary platform technology that delivers drugs via the sublingual (under the tongue)
route. This unique method delivers drugs to the bloodstream quickly and with minimal drug breakdown in the liver and gastro-intestinal system, a
process that can greatly reduce side effects while also requiring a lower dosage than conventional oral drugs while generally still producing the
same results. Additionally, GHLV is also developing oral formulations of drugs which are intended to cause fewer stomach side effects than
formulations of such drugs previously marketed by other pharmaceutical companies. GHLV's drug formulations are specifically designed to
deliver drugs to the blood stream rapidly and more efficiently than traditional drug formulations but with fewer side effects.
GHLV intends to develop its products to the final stage of marketing. If additional clinical trials are necessary to support regulatory filings, GHLV
management plans to do so in-house. The Company also plans to market the products through direct consumer sources such as advertisements
on the internet, television, radio and in magazines, while signing up co-marketing partners. These partners would typically be larger specialty
pharmaceutical companies and distributors. In the latter case, GHLV plans to share the revenue on a pre-arranged royalty basis structure.
Investors should keep in mind this is a costly endeavor, however, GHLV management anticipates its products, and any new product, will require
substantial funding.
GHLV recently filed a new patent under the Patent Corporation Treaty program on its sublingual drug delivery technology. Under the Patent
Corporation Treaty rule, a patented discovery can be protected in over 80 countries, including China and the United States. The patent, which is
entitled "Method of delivering a pharmaceutical composition sublingually", is a new proprietary formulation. The formulation is designed to deliver
small molecules such as life style drugs to larger macromolecules rapidly to the blood avoiding gastric and hepatic breakdown.
Drug X-Excite
Erectile dysfunction is a physical condition that affects 10% of men worldwide. The current treatment is the use of drugs that prevent the enzyme
5-phosphodiesterase.
Most notable products of this class are Viagra, Cialis, and Levitra, which collectively generate over $3 billion annually. All
of them carry a considerable side effects due to gastric and colonic absorption, these include acidoses (gas build up), stool run, and many more.
GHLV has a new formulation of these products which bypasses all the gastrointestinal side effects, making the drug far more patient friendly and
desirable.
Drug T-Slim
Obesity is one of our biggest problems, no pun intended. According to many medical experts, obesity is the foundation for much of our medical
problems. It is estimated that 20% of American are obese and another 40% are overweight. While exercise is one way to battle obesity, many
different food formulations, herbal products, and pharmaceutical products are being used to help reduce the appetite, which allows people to
lose weight. While the anti-obesity market for products and processes are estimated at $5 billion, very little success has been reported.
Most
people going through the severe forms of exercise and diet regain their weight within a few months of stopping their program The vicious cycle of
losing and gaining weight, which is known as yo-yo dieting, is not only frustrating, but unhealthy as well. Most weight loss consumers desire a
system which allows the body to stay lean for long time after considerable weight loss. GHLV is developing new drugs which will do exactly that.
Once a person has lost weight through the exercise and diet process, by using T-Slim he or she could manage to maintain weight loss as T-Slim
works to curb the appetite.
Drug
Nico-Z
Addiction to alcohol, tobacco and controlled substances are a major social and health care issue. More than $10 Billion is spent on addiction
and addictive products, which, in our opinion, provides a never ending and growing market. From developing to developed countries, societies
face a mountain of social and economic problem. The world is seeking a solution to curb the growth of this industry. GHLV is on the forefront of
this issue by bringing new technology to curb the addiction and its growth through society.
Relax-B
Relax-B is designed to cause relaxation of muscles leading to stress relief. This relatively new product from GHLV uses an already FDA
approved drug with a special formulation at a very low dosage designed to reach blood rapidly. The anti-stress market is estimated to be over $5
billion and is currently growing at an unprecedented rate due to socio-economic problems associated with daily life. While there is no cure, the
effective treatment can provide people with better life and greater productivity.
Stress or depression is a chronic disease that can involve lifetime
intervention. While currently almost all the anti-stress medications are slow acting and sometimes require months for patients to see the effect,
the need for rapid anti-stress medications is highly desirable. GHLV is focused on developing such rapid acting medications. In our opinion, this
makes GHLV's technology unique and allows the Company to develop such products.
Summary
Opportunities in the stock market are not always so clearly defined and certainly do not happen often. We believe GHLV has the potential to
make its business plan a reality and its shareholder profits on the stock. We would suggest getting in early on GHLV and taking a look at the their
website for more information.
